Drug Pricing

Pharmalot By Ed Silverman

A CVS whistleblower lawsuit comes at a pivotal moment for the FTC’s probe of pharma and PBMs

Pharmalot By Ed Silverman

Pharmalittle: Senate bill would allow insulin makers to lock in profits; GSK, Novartis pledge funds for diseases that mostly affect the poor

Pharmalot By Ed Silverman

Industry-funded studies on cost-effectiveness often favor pricier drugs, study finds

Pharmalot By Ed Silverman

Pharmalittle: Medicare could have saved billions if it paid what Cuban charges; India’s drug controller accused of taking bribe

Pharmalot By Ed Silverman

Pharmalittle: Lawmakers urge FTC to probe blood thinner prices; EU pressures Covid vaccine makers to renegotiate contracts

Pharmalot By Ed Silverman

A widely anticipated ALS drug wouldn’t be cost effective if priced the same as an older rival

Exclusive By Rachel Cohrs

Klobuchar, Porter call for FTC to investigate price hikes by Janssen, Bristol Myers Squibb

First Opinion By Maureen Testoni

Pursuit of profits is driving drug companies to break the 340B law

Pharmalot By Ed Silverman

How high? Prices for newly launched medicines rose 20% annually, analysis finds

Pharmalot By Ed Silverman

FTC will investigate pharmacy benefit managers and their role in prescription drug costs

a photo of a person with brown hair pulled back and wearing glasses, in a black blazer, speaking in front of a microphone at a lectern

Pharmalot By Ed Silverman

‘All about strengthening health systems’: New coalition pushes to license cancer drugs to low-income countries

Pharmalot By Ed Silverman

Italian authorities fine drugmaker for ‘excessive’ pricing of a rare disease drug

D.C. Diagnosis By Rachel Cohrs

California senators advance three bills meant to crack down on health insurers

D.C. Diagnosis By Nicholas Florko

A no good, very bad week for the FDA

D.C. Diagnosis By Rachel Cohrs

AstraZeneca’s ambitious vaccine dreams are finally, officially dead

Pharmalot By Ed Silverman

‘Pharma bro’ Martin Shkreli released from prison

First Opinion By Billy Kenber

The man behind ‘value-based pricing’ saw pharma distorting his message — and walked away

Pharmalot By Ed Silverman

Arkansas becomes the latest state to sue drugmakers and PBMs over insulin pricing

Pharmalot By Ed Silverman

Lawmakers wade into a contentious battle over orphan drug monopolies

D.C. Diagnosis By Nicholas Florko

Pharma showers John Thune with campaign cash

Pharmalot By Ed Silverman

J&J sues a behind-the-scenes company for exploiting its patient assistance program

D.C. Diagnosis By Nicholas Florko

The FDA’s Rob Califf on importing drugs from Canada, on Aduhelm, and on opioids

Politics By Rachel Cohrs

Would drugmakers lower their insulin prices if Congress asks nicely?

Pharmalot By Ed Silverman

California fines an OptumRx pharmacy for jeopardizing patient health. Is that enough?

Pharmalot By Ed Silverman

Most Read

Medicare could have saved billions on drugs if it paid what Mark Cuban charges at his new pharmacy

European Commission investigates Vifor for ‘disparaging’ its only rival in iron deficiency market

Lawmakers ask GAO to probe pharmacy benefit managers over their role in drug pricing

Reformulating drugs helps profits more than patients

FTC puts drugmakers and PBMs on notice that it will crack down on illegal rebate schemes

A ‘veritable playground’: CVS whistleblower details how patients were charged higher drug prices

Supreme Court sides with hospitals on Medicare drug pay dispute

The Senate health committee finally marks up its user fee bill

All Coverage

A CVS whistleblower lawsuit comes at a pivotal moment for the FTC’s probe of pharma and PBMs

Pharmalittle: Senate bill would allow insulin makers to lock in profits; GSK, Novartis pledge funds for diseases that mostly affect the poor

Industry-funded studies on cost-effectiveness often favor pricier drugs, study finds

Pharmalittle: Medicare could have saved billions if it paid what Cuban charges; India’s drug controller accused of taking bribe

Pharmalittle: Lawmakers urge FTC to probe blood thinner prices; EU pressures Covid vaccine makers to renegotiate contracts

A widely anticipated ALS drug wouldn’t be cost effective if priced the same as an older rival

Klobuchar, Porter call for FTC to investigate price hikes by Janssen, Bristol Myers Squibb

Pursuit of profits is driving drug companies to break the 340B law

How high? Prices for newly launched medicines rose 20% annually, analysis finds

FTC will investigate pharmacy benefit managers and their role in prescription drug costs

‘All about strengthening health systems’: New coalition pushes to license cancer drugs to low-income countries

Italian authorities fine drugmaker for ‘excessive’ pricing of a rare disease drug

California senators advance three bills meant to crack down on health insurers

A no good, very bad week for the FDA

AstraZeneca’s ambitious vaccine dreams are finally, officially dead

‘Pharma bro’ Martin Shkreli released from prison

The man behind ‘value-based pricing’ saw pharma distorting his message — and walked away

Arkansas becomes the latest state to sue drugmakers and PBMs over insulin pricing

Lawmakers wade into a contentious battle over orphan drug monopolies

Pharma showers John Thune with campaign cash

J&J sues a behind-the-scenes company for exploiting its patient assistance program

The FDA’s Rob Califf on importing drugs from Canada, on Aduhelm, and on opioids

Would drugmakers lower their insulin prices if Congress asks nicely?

California fines an OptumRx pharmacy for jeopardizing patient health. Is that enough?

Usual and customary? Rite Aid ordered to pay Humana $123 million for inflating pharmacy claims

Subscribe to STAT for $15 per month lorem ipsum